🚀 VC round data is live in beta, check it out!
Stoke Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Stoke Therapeutics and similar public comparables like Celldex Therapeutics, Nektar Therapeutics, Eris Lifesciences, Bora Pharmaceuticals and more.
Stoke Therapeutics Overview
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Founded
2014
HQ
Employees
128
Website
Sectors
Financials (LTM)
EV
$2B
Stoke Therapeutics Financials
Stoke Therapeutics reported last 12-month revenue of $150M and negative EBITDA of ($47M).
In the same LTM period, Stoke Therapeutics generated $150M in gross profit, ($47M) in EBITDA losses, and had net loss of ($48M).
Revenue (LTM)
Stoke Therapeutics P&L
In the most recent fiscal year, Stoke Therapeutics reported revenue of $184M and EBITDA of ($3M).
Stoke Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $150M | XXX | $184M | XXX | XXX | XXX |
| Gross Profit | $150M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($47M) | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | (32%) | XXX | (2%) | XXX | XXX | XXX |
| EBIT Margin | (41%) | XXX | (9%) | XXX | XXX | XXX |
| Net Profit | ($48M) | XXX | ($3M) | XXX | XXX | XXX |
| Net Margin | (32%) | XXX | (2%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Stoke Therapeutics Stock Performance
Stoke Therapeutics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Stoke Therapeutics' stock price is $34.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStoke Therapeutics Valuation Multiples
Stoke Therapeutics trades at 11.4x EV/Revenue multiple, and (36.3x) EV/EBITDA.
EV / Revenue (LTM)
Stoke Therapeutics Financial Valuation Multiples
As of March 21, 2026, Stoke Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Stoke Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stoke Therapeutics has a P/E ratio of (41.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 11.4x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBITDA | (36.3x) | XXX | (522.8x) | XXX | XXX | XXX |
| EV/EBIT | (28.0x) | XXX | (102.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 11.4x | XXX | — | XXX | XXX | XXX |
| P/E | (41.0x) | XXX | (669.1x) | XXX | XXX | XXX |
| EV/FCF | (238.8x) | XXX | 38.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Stoke Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Stoke Therapeutics Margins & Growth Rates
Stoke Therapeutics' revenue in the last 12 month declined by (79%).
Stoke Therapeutics' revenue per employee in the last FY averaged $1.2M.
Stoke Therapeutics' rule of 40 is (110%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Stoke Therapeutics' rule of X is (229%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Stoke Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (79%) | XXX | (85%) | XXX | XXX | XXX |
| EBITDA Margin | (32%) | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Growth | 334% | XXX | 6195% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (110%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (229%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 36% | XXX | 36% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 95% | XXX | 75% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 111% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Stoke Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Celldex Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nektar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Eris Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Bora Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Olema Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stoke Therapeutics M&A Activity
Stoke Therapeutics acquired XXX companies to date.
Last acquisition by Stoke Therapeutics was on XXXXXXXX, XXXXX. Stoke Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Stoke Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStoke Therapeutics Investment Activity
Stoke Therapeutics invested in XXX companies to date.
Stoke Therapeutics made its latest investment on XXXXXXXX, XXXXX. Stoke Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Stoke Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Stoke Therapeutics
| When was Stoke Therapeutics founded? | Stoke Therapeutics was founded in 2014. |
| Where is Stoke Therapeutics headquartered? | Stoke Therapeutics is headquartered in United States. |
| How many employees does Stoke Therapeutics have? | As of today, Stoke Therapeutics has over 128 employees. |
| Who is the CEO of Stoke Therapeutics? | Stoke Therapeutics' CEO is Ian F. Smith. |
| Is Stoke Therapeutics publicly listed? | Yes, Stoke Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Stoke Therapeutics? | Stoke Therapeutics trades under STOK ticker. |
| When did Stoke Therapeutics go public? | Stoke Therapeutics went public in 2019. |
| Who are competitors of Stoke Therapeutics? | Stoke Therapeutics main competitors are Celldex Therapeutics, Nektar Therapeutics, Eris Lifesciences, Bora Pharmaceuticals. |
| What is the current market cap of Stoke Therapeutics? | Stoke Therapeutics' current market cap is $2B. |
| What is the current revenue of Stoke Therapeutics? | Stoke Therapeutics' last 12 months revenue is $150M. |
| What is the current revenue growth of Stoke Therapeutics? | Stoke Therapeutics revenue growth (NTM/LTM) is (79%). |
| What is the current EV/Revenue multiple of Stoke Therapeutics? | Current revenue multiple of Stoke Therapeutics is 11.4x. |
| Is Stoke Therapeutics profitable? | No, Stoke Therapeutics is not profitable. |
| What is the current EBITDA of Stoke Therapeutics? | Stoke Therapeutics has negative EBITDA and is not profitable. |
| What is Stoke Therapeutics' EBITDA margin? | Stoke Therapeutics' last 12 months EBITDA margin is (32%). |
| What is the current EV/EBITDA multiple of Stoke Therapeutics? | Current EBITDA multiple of Stoke Therapeutics is (36.3x). |
| What is the current FCF of Stoke Therapeutics? | Stoke Therapeutics' last 12 months FCF is ($7M). |
| What is Stoke Therapeutics' FCF margin? | Stoke Therapeutics' last 12 months FCF margin is (5%). |
| What is the current EV/FCF multiple of Stoke Therapeutics? | Current FCF multiple of Stoke Therapeutics is (238.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.